Skip to main content
  • CAPTIVA

    The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

    Investigator
    Anna Y Khanna
    Ages
    30 Years - N/A
    Sexes
    All
  • CAPTIVA

    The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

    Investigator
    Brian L Hoh
    Ages
    30 Years - N/A
    Sexes
    All